These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 15607844)

  • 1. The impact of injecting drug use status on hepatitis C-related referral and treatment.
    Stoové MA; Gifford SM; Dore GJ
    Drug Alcohol Depend; 2005 Jan; 77(1):81-6. PubMed ID: 15607844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Australian men's experiences of living with hepatitis C virus: results from a cross-sectional survey.
    Gifford SM; O'Brien ML; Smith A; Temple-Smith M; Stoové M; Mitchell D; Jolley D
    J Gastroenterol Hepatol; 2005 Jan; 20(1):79-86. PubMed ID: 15610451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk behaviors and antibody hepatitis B and C prevalence among injecting drug users in south-western Sydney, Australia.
    Maher L; Chant K; Jalaludin B; Sargent P
    J Gastroenterol Hepatol; 2004 Oct; 19(10):1114-20. PubMed ID: 15377287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Knowledge and attitudes about treatment for hepatitis C virus infection and barriers to treatment among current injection drug users in Australia.
    Doab A; Treloar C; Dore GJ
    Clin Infect Dis; 2005 Apr; 40 Suppl 5():S313-20. PubMed ID: 15768340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales.
    Sutton AJ; Gay NJ; Edmunds WJ; Hope VD; Gill ON; Hickman M
    BMC Infect Dis; 2006 Jun; 6():93. PubMed ID: 16762050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy.
    Hallinan R; Byrne A; Amin J; Dore GJ
    J Gastroenterol Hepatol; 2005 Jul; 20(7):1082-6. PubMed ID: 15955218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Referral for chronic hepatitis C treatment from a drug dependency treatment setting.
    Hallinan R; Byrne A; Agho K; Dore GJ
    Drug Alcohol Depend; 2007 Apr; 88(1):49-53. PubMed ID: 17067763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment for hepatitis C virus infection among current injection drug users in Australia.
    Matthews G; Kronborg IJ; Dore GJ
    Clin Infect Dis; 2005 Apr; 40 Suppl 5():S325-9. PubMed ID: 15768342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Markers and risk factors for HCV, HBV and HIV in a network of injecting drug users in Melbourne, Australia.
    Miller ER; Hellard ME; Bowden S; Bharadwaj M; Aitken CK
    J Infect; 2009 May; 58(5):375-82. PubMed ID: 19328555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The costs of not treating hepatitis C virus infection in injecting drug users in New Zealand.
    Sheerin IG; Green FT; Sellman JD
    Drug Alcohol Rev; 2003 Jun; 22(2):159-67. PubMed ID: 12850902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach.
    Birkhead GS; Klein SJ; Candelas AR; O'Connell DA; Rothman JR; Feldman IS; Tsui DS; Cotroneo RA; Flanigan CA
    Int J Drug Policy; 2007 Oct; 18(5):417-25. PubMed ID: 17854731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular epidemiologic analysis of hepatitis C virus infection in injecting drug users with acute hepatitis C in Japan.
    Satoh Y; Hino K; Kato T; Mizokami M; Yamashita S; Nakamura H; Okita K
    J Gastroenterol Hepatol; 2004 Nov; 19(11):1305-11. PubMed ID: 15482539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C-related discrimination among heroin users in Sydney: drug user or hepatitis C discrimination?
    Day C; Ross J; Dolan K
    Drug Alcohol Rev; 2003 Sep; 22(3):317-21. PubMed ID: 15385226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C virus infection, HIV co-infection, and associated risk among injecting drug users in Togliatti, Russia.
    Rhodes T; Platt L; Judd A; Mikhailova LA; Sarang A; Wallis N; Alpatova T; Hickman M; Parry JV
    Int J STD AIDS; 2005 Nov; 16(11):749-54. PubMed ID: 16303071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irish injecting drug users and hepatitis C: the importance of the social context of injecting.
    Smyth BP; Barry J; Keenan E
    Int J Epidemiol; 2005 Feb; 34(1):166-72. PubMed ID: 15513970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of hepatitis C in an ethnically diverse HIV-1-infected cohort in south London.
    Mohsen AH; Murad S; Easterbrook PJ
    HIV Med; 2005 May; 6(3):206-15. PubMed ID: 15876288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in hepatitis C-related liver disease in a large clinic population.
    Ostapowicz G; Dallinger M; Bell SJ; Strasser SI; Watson KJ; Slavin J; Santamaria J; Desmond PV
    Intern Med J; 2001 Mar; 31(2):90-6. PubMed ID: 11480484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methadone maintenance and hepatitis C virus infection among injecting drug users.
    Crofts N; Nigro L; Oman K; Stevenson E; Sherman J
    Addiction; 1997 Aug; 92(8):999-1005. PubMed ID: 9376782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology and natural history of hepatitis C virus infection in injection drug users: implications for treatment.
    Sulkowski MS; Thomas DL
    Clin Infect Dis; 2005 Apr; 40 Suppl 5():S263-9. PubMed ID: 15768333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of, and risk factors for, hepatitis C virus infection among recent initiates to injecting in London and Glasgow: cross sectional analysis.
    Judd A; Hutchinson S; Wadd S; Hickman M; Taylor A; Jones S; Parry JV; Cameron S; Rhodes T; Ahmed S; Bird S; Fox R; Renton A; Stimson GV; Goldberg D
    J Viral Hepat; 2005 Nov; 12(6):655-62. PubMed ID: 16255768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.